Core Insights - Dogwood Therapeutics, Inc. is a development-stage biotechnology company focused on creating new medicines for pain management [1] - The Chief Medical Officer will present the Halneuron® pain management research program at the 19th Annual Pain Therapeutics Summit on October 14, 2025 [1] - Halneuron® is a highly purified version of tetrodotoxin aimed at treating Chemotherapy Induced Neuropathic Pain (CINP) [1] Company Overview - Dogwood Therapeutics is engaged in the development of innovative treatments for pain, specifically targeting conditions arising from chemotherapy [1] - The company is in the development stage, indicating ongoing research and potential future product offerings [1] Research Program Details - The Halneuron® program focuses on addressing peripheral neuropathic pain that occurs after chemotherapy with certain agents [1] - The presentation at the Pain Therapeutics Summit will provide insights into the research and development progress of Halneuron® [1]
Dogwood Therapeutics, Inc. Chief Medical Officer, Dr. Michael Gendreau, to Present an Overview of the Halneuron® Pain Research Program at the 19th Annual Pain Therapeutics Summit